Figure 2
From: Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
OX40 and OX40L expression on primary AML cells and association with clinical parameters. Frequencies of OX40 (a) and OX40L (b) positive blasts according to the different FAB classifications (single values, median, Kruskal–Wallis test) are showed. The expression of OX40 (c) and OX40L (d) was analyzed on FAB M0-M2 vs. FAB M4-M5 (min/max whiskers, Mann–Whitney-U test). The expression of OX40 (e) and OX40L (f) was analyzed primary (pAML) vs. secondary (sAML) AML (min/max whiskers, Mann–Whitney-U test). Distribution of OX40 (g) and OX40L (h) expression (%) throughout NCCN risk group (min/max whiskers, Kruskal–Wallis test) is showed.
